If you're developing a healthtech product, understanding NICE's priorities is crucial. For 2024/25, NICE is focussing on innovations addressing: ...

Final NICE guidance recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma ...

New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...

We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) ...

All NICE products on oesophageal cancer. Includes any guidance and quality standards.

We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136] Draft guidance Technology appraisal guidance 3 March ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Mental wellbeing is about life satisfaction, optimism, self-esteem, feeling in control, having a purpose and a sense of belonging and support. Older people, including those living in care homes, often ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.